Key result
Latest-generation CAS yields a ~9% 6-month stroke or death rate in patients ineligible for endarterectomy.
Why the study?
Does carotid angioplasty and stenting with latest-generation self-expanding stents provide a safe alternative in patients with symptomatic extracranial internal carotid artery stenosis who are ineligible for carotid endarterectomy?
Population
23 consecutive patients with symptomatic extracranial internal carotid artery stenosis who were adjudicated…
Design
Cohort, open-label
Follow-up
6 months
Authors
Loading...
CAS may serve as alternative for high-risk CEA candidates; leaves open whether newer stents improve outcomes versus prior generations.
Cohort (n=23)
Open-label
No
Does carotid angioplasty and stenting with latest-generation self-expanding stents provide a safe alternative in patients with symptomatic extracranial internal carotid artery stenosis who are ineligible for carotid endarterectomy?
Carotid angioplasty and stenting with latest-generation self-expanding stents appears to be a safe and valid alternative for patients with severe symptomatic carotid stenosis who are ineligible for endarterectomy.
Linfante et al. (2004) conducted a cohort in Symptomatic extracranial internal carotid artery stenosis (≥70%) (n=23). Carotid angioplasty and stenting (CAS) with latest-generation self-expanding stents was evaluated on Death and all strokes (ipsilateral and contralateral). Carotid angioplasty and stenting with latest-generation self-expanding stents in patients ineligible for endarterectomy resulted in a 9% rate of primary adverse events (stroke or death) at 6 months.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: